A systematic review of peptide-based serological tests for the diagnosis of leishmaniasis

Abstract

Serological methods should meet the needs of leishmaniasis diagnosis due to their high sensitivity and specificity, economical and adaptable rapid diagnostic test format, and ease of use. Currently, the performances of serological diagnostic tests, despite improvements with recombinant proteins, vary greatly depending on the clinical form of leishmaniasis and the endemic area. Peptide-based serological tests are promising as they could compensate for antigenic variability and improve performance, independently of Leishmania species and subspecies circulating in the endemic areas. The objective of this systematic review was to inventory all studies published from 2002 to 2022 that evaluate synthetic peptides for serological diagnosis of human leishmaniases and also to highlight the performance (e.g., sensitivity and specificity) of each peptide reported in these studies. All clinical forms of leishmaniasis, visceral and tegumentary, and all Leishmania species responsible for these diseases were considered. Following PRISMA statement recommendations, 1,405 studies were identified but only 22 articles met the selection criteria and were included in this systematic review. These original research articles described 77 different peptides, of which several have promising performance for visceral or tegumentary leishmaniasis diagnosis. This review highlights the importance of and growing interest in synthetic peptides used for serological diagnosis of leishmaniases, and their performances compared to some widely used tests with recombinant proteins.

Mucosal Relapse of Visceral Leishmaniasis in a Child with SARS-CoV-2 Infection

“…Traditionally, the gold standard for diagnosis has been a microscopic examination (after Giemsa staining) or a culture on invasive samples (spleen, bone marrow or lymph node aspirates, or liver biopsy) [ 32 ]. The performances of serological diagnostic tests, despite improvements with recombinant proteins, critically depend on the clinical form of leishmaniasis and the endemic area [ 33 ].…”